A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Clinical trial NCT05635487 · RECRUITING
Trial details
- NCT number
- NCT05635487
- Sponsor
- Shengjing Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-16
- Primary completion
- 2025-02-28
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.